» Articles » PMID: 24577967

Myocardial Extracellular Matrix: an Ever-changing and Diverse Entity

Overview
Journal Circ Res
Date 2014 Mar 1
PMID 24577967
Citations 163
Authors
Affiliations
Soon will be listed here.
Abstract

The cardiac extracellular matrix (ECM) is a complex architectural network consisting of structural and nonstructural proteins, creating strength and plasticity. The nonstructural compartment of the ECM houses a variety of proteins, which are vital for ECM plasticity, and can be divided into 3 major groups: glycoproteins, proteoglycans, and glycosaminoglycans. The common denominator for these groups is glycosylation, which refers to the decoration of proteins or lipids with sugars. This review will discuss the fundamental role of the matrix in cardiac development, homeostasis, and remodeling, from a glycobiology point of view. Glycoproteins (eg, thrombospondins, secreted protein acidic and rich in cysteine, tenascins), proteoglycans (eg, versican, syndecans, biglycan), and glycosaminoglycans (eg, hyaluronan, heparan sulfate) are upregulated on cardiac injury and regulate key processes in the remodeling myocardium such as inflammation, fibrosis, and angiogenesis. Albeit some parallels can be made regarding the processes these proteins are involved in, their specific functions are extremely diverse. In fact, under varying conditions, individual proteins can even have opposing functions, making spatiotemporal contribution of these proteins in the rearrangement of multifaceted ECM very hard to grasp. Alterations of protein characteristics by the addition of sugars may explain the immense, yet tightly regulated, variability of the remodeling cardiac matrix. Understanding the role of glycosylation in altering the ultimate function of glycoproteins, proteoglycans, and glycosaminoglycans in the myocardium may lead to the development of new biochemical structures or compounds with great therapeutic potential for patients with heart disease.

Citing Articles

Hydrogels for Cardiac Tissue Regeneration: Current and Future Developments.

Holme S, Richardson S, Bella J, Pinali C Int J Mol Sci. 2025; 26(5).

PMID: 40076929 PMC: 11900105. DOI: 10.3390/ijms26052309.


Model construction and clinical therapeutic potential of engineered cardiac organoids for cardiovascular diseases.

Wang Y, Hou Y, Hao T, Garcia-Contreras M, Li G, Cretoiu D Biomater Transl. 2025; 5(4):337-354.

PMID: 39872935 PMC: 11764187. DOI: 10.12336/biomatertransl.2024.04.002.


3D-Printed Myocardium-Specific Structure Enhances Maturation and Therapeutic Efficacy of Engineered Heart Tissue in Myocardial Infarction.

Wu Y, Wang Y, Xiao M, Zhang G, Zhang F, Tang M Adv Sci (Weinh). 2025; 12(10):e2409871.

PMID: 39840547 PMC: 11905000. DOI: 10.1002/advs.202409871.


The role of the extracellular matrix in cardiac regeneration.

Wang X, Yu S, Xie L, Xiang M, Ma H Heliyon. 2025; 11(1):e41157.

PMID: 39834404 PMC: 11745795. DOI: 10.1016/j.heliyon.2024.e41157.


Harnessing synergistic effects of MMP-2 Inhibition and bFGF to simultaneously preserve and vascularize cardiac extracellular matrix after myocardial infarction.

Niu H, Liu Z, Guan Y, Wen J, Dang Y, Guan J Acta Biomater. 2024; 191:189-204.

PMID: 39532649 PMC: 11659021. DOI: 10.1016/j.actbio.2024.10.050.